risk of thyroid cancer with semaglutide Assessment Carcinogenic and Safety Profile of GLP1-RA (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review GLP-1 agonist drugs like Ozempic

community oncology practices found GLP-1 use was associated with significantly better overall survival across six tumor types breast, prostate, colorectal, lung, liver and kidney with a roughly one-third reduction in the risk of death

S2CID 27606314

Tirzepatide has demonstrated cardiovascular safety in clinical trials, but patients should report symptoms like chest pain, severe shortness of breath, or rapid irregular heartbeat immediately

Conclusion Retatrutide is a triple receptor agonist peptide studied for GLP-1, GIP, and glucagon receptor signalling in metabolic research

Trends Cell Biol (2014) 24(8):45563

It is a weekly injection that contains the active ingredient semaglutide